Exelixis Inc. reports developments from its oncology business, including commercial performance for the cabozantinib franchise and clinical and regulatory updates across cancer programs. The company discovers, develops and commercializes cancer medicines, with CABOMETYX® (cabozantinib) as its flagship commercial product and COMETRIQ® also part of its cabozantinib portfolio.
Recurring updates include quarterly financial results, product revenue trends, financial guidance, pipeline milestones and investor conference presentations. Exelixis also discusses zanzalintinib, an investigational oral kinase inhibitor, and a broader pipeline of small molecules and biotherapeutics targeting additional tumor types and indications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Exelixis, Inc. (NASDAQ: EXEL) will release its Q1 2023 financial results on May 9, 2023, after market close. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and provide a business update. Investors can access the call via registration on the company’s website. Exelixis is dedicated to developing innovative treatments for cancer, focusing on expanding its product portfolio and advancing its flagship product, CABOMETYX®. The company aims to enhance cancer care through its robust pipeline and collaborations.
Exelixis, Inc. (Nasdaq: EXEL) announced that Carl Feldbaum and Vincent Marchesi will not seek re-election to the Board of Directors during the 2023 Annual Meeting of Stockholders. The Board is nominating Tomas Heyman and Robert Oliver as independent directors to fill their positions. This decision follows unsuccessful settlement negotiations with Farallon Capital Management regarding board member nominations and access to company information. Dr. Stelios Papadopoulos expressed gratitude toward Feldbaum and Marchesi for their service. The upcoming board election aims to enhance corporate governance. Following the election, the Board will consist of 11 members, 10 of whom are independent. The Annual Meeting date has yet to be announced.